Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0006632003
Fri, 21.10.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, October 21, 2022
MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
Preliminary Q3 2022 Monjuvi U.S. net product sales of US$ 22.2 million (€ 21.9 million)
Anticipated full year 2022 Monjuvi U.S. net product sales of approximately US$ 90 million
Morpho [ … ]
Fri, 21.10.2022
MorphoSys AG
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014
Planegg/Munich, Germany, October 21, 2022
Ad hoc: MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
Preliminary Q3 2022 Monjuvi U.S. net product sales of US$ 22.2 million (€ 21.9 million)
Ant [ … ]
Fri, 21.10.2022
MorphoSys AG
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014
Planegg/Munich, Germany, October 21, 2022
Ad hoc: MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
Preliminary Q3 2022 Monjuvi U.S. net product sales of US$ 22.2 million (€ 21.9 million)
Ant [ … ]
Wed, 28.09.2022
MorphoSys AG
Media Release
BOSTON, Mass., USA, September 28, 2022
MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL
The findings, including data from patients treated with the targeted immunotherapy for 5 years or more, will be presented during the Tenth [ … ]
Wed, 28.09.2022
MorphoSys AG
Media Release
BOSTON, Mass., USA, September 28, 2022
MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL
The findings, including data from patients treated with the targeted immunotherapy for 5 years or more, will be presented during the Tenth [ … ]
Wed, 31.08.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, August 31, 2022
MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters
Tim Demuth, M.D., Ph.D., has more than 20 years of broad leadership experience in drug development, with a focus in oncology
MorphoSys AG (FSE: MOR; NASDAQ: MOR) ann [ … ]
Wed, 31.08.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, August 31, 2022
MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters
Tim Demuth, M.D., Ph.D., has more than 20 years of broad leadership experience in drug development, with a focus in oncology
MorphoSys AG (FSE: MOR; NASDAQ: MOR) ann [ … ]
Wed, 03.08.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, August 3, 2022
MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
Monjuvi® U.S. net product sales of US$ 23.3 million (€ 21.7 million) for the second quarter 2022, a 25% Q-Q growth and 29% Y-Y growth
Efficacy and safety data of pelabresib for potential treatment improvement in myelof [ … ]
Wed, 03.08.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, August 3, 2022
MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
Monjuvi® U.S. net product sales of US$ 23.3 million (€ 21.7 million) for the second quarter 2022, a 25% Q-Q growth and 29% Y-Y growth
Efficacy and safety data of pelabresib for potential treatment improvement in myelof [ … ]
Thu, 28.07.2022
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, July 28, 2022
Invitation to MorphoSys’ Second Quarter and First Half Year 2022 Results Conference Call on August 4, 2022
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the second quarter and first half year 2022 results on August 3, 2022 at 10:00 pm CEST (9:00 pm BST; 4:0 [ … ]